8-K filed Aug 4, 2026 at 16:10 ET
Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing consensus of $0.91 by 3.3%. The company raised full-year 2026 revenue guidance to $285-295M (from $275-290M), reflecting strong core product sales momentum. The in-license of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2- breast cancer, expands the commercial portfolio, but the $70M upfront payment drew down cash to $95.3M from $155M at year-end 2025.